

**Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard
Prophylaxis in Adults with Severe Hemophilia A in China**

Congling Gu, Masters¹, Hui Huang, Masters¹, Yi Han, PhD^{2*}

¹Medical Affairs, Takeda Pharmaceutical Company Ltd, Beijing, China

²Sun Yat-sen University, Guangzhou, China

*Corresponding author

Yi Han


Sun Yat-sen University,

No.132 Waihuan East Road, Guangzhou, China, 510006

[Email ID: yihan2k5@gmail.com](mailto:yihan2k5@gmail.com)

Phone: +01-9739088381


Supplementary Figure 1. Curve of AJBR with FVIII concentration change.



Data source: Den Uijl et al. (2011) [26]


AJBR, annual joint bleed rate

Supplementary Figure 2. Trough distribution standard prophylaxis and PK-guided prophylaxis.



PK, pharmacokinetic; PRO, prophylaxis; STD, standard

Supplementary Figure 3. AJBR: standard prophylaxis and PK-guided prophylaxis.



AJBR, annual joint bleed rate; PK, pharmacokinetic; PRO, prophylaxis; STD, standard

Supplementary Table 1. AJBR under different FVIII concentrations

FVIII Concentration (IU/dL)	AJBR
≥12	0.15
11.5-12	0.16
11-11.5	0.17
10.5-11	0.2706
10-10.5	0.4364
9.5-10	0.5612
9-9.5	0.6586
8.5-9	0.7208
8-8.5	0.7521
7.5-8	0.7788
7-7.5	0.8007
6.5-7	0.8093
6-6.5	0.8066
5.5-6	0.8219
5-5.5	0.8779
4.5-5	1.0586
4-4.5	1.3225
3.5-4	1.5350
3-3.5	2.1640
2.5-3	3.5841
2-2.5	4.7960
1.5-2	5.2679
1-1.5	5.5031
≤1	18

AJBR, annual joint bleed rate.

Supplementary Table 2. Data Related to the Use of ADVATE® in the Treatment of Bleeding

Parameter	Estimated Value	Distribution	Source
Single injection dose of rFVIII (IU/kg)	26.85	Constant	Expert survey
Administration frequency	Twice daily	Constant	Expert survey
Average treatment duration (days)	1.9	SD: 0.54772	Expert survey

ADVATE®, recombinant human coagulation factor VIII for injection.

Supplementary Table 3. Utility Values of Health Status in Patients With Severe Hemophilia A

		Source
State	Utility Value	
Non-bleeding period	0.84	29
Bleeding period	0.64	29

Supplementary Table 4. Cost Data of ADVATE® in China

Parameter	Estimated Value	Source
ADVATE®		
Price (USD)	471.33	30
Specifications	1,000 IU	30
Price per unit (USD)	0.47	—
Cost of prophylaxis		
Standard (USD/kg/time)	14.14	—
Cost of bleeding treatment (USD/kg/time)	12.66	—

ADVATE®, recombinant human coagulation factor VIII for injection; USD, United States dollar.

Supplementary Table 5. Single Injection Dose Comparison

Single Injection Dose of PK-Guided Individualized Prophylaxis	Proportion (%)
Less than 30 IU/kg	34.50
Equal to 30 IU/kg	57.35
Higher than 30 IU/kg	8.15

PK, pharmacokinetic